Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells $121,800.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Dawn Halkuff sold 20,000 shares of Xeris Biopharma stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $121,800.00. Following the transaction, the director directly owned 95,000 shares of the company’s stock, valued at approximately $578,550. The trade was a 17.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $6.18 on Monday. The stock has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The business has a fifty day moving average of $6.10 and a two-hundred day moving average of $6.59. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.30 and a 52-week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Institutional Trading of Xeris Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers increased its stake in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after buying an additional 1,735 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after buying an additional 1,820 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Xeris Biopharma by 6.5% in the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after buying an additional 2,351 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Xeris Biopharma by 17.7% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 16,070 shares of the company’s stock valued at $126,000 after buying an additional 2,420 shares in the last quarter. Finally, AlphaCentric Advisors LLC increased its stake in shares of Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after buying an additional 2,494 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on XERS shares. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.